Download MendeleyKnowledge and Structure-Based Drug Design of 15-PGDH Inhibitors.
Dodda, L.S., Campos, S., Ciccone, D., Carreiro, S., Leit, S., Brennan, D., Zephyr, J., Jacques-O'Hagan, S., Kumar, S., Kuo, F.S., Shaik, M.M., Price, D.J., Loh, C., Edmondson, S.D., Tummino, P., Kaila, N.(2025) J Med Chem 68: 18436-18462
- PubMed: 40864846
- DOI: https://doi.org/10.1021/acs.jmedchem.5c01231
- Primary Citation of Related Structures:
9PFL, 9PFM - PubMed Abstract:
PGE2 plays important roles in immune cell function and in potentiating tissue regeneration. 15-PGDH is the key enzyme involved in inactivation of PGE2 and its inhibition therefore provides valuable therapeutic opportunity. We have solved the first cocrystal structure of 15-PGDH bound to small molecule inhibitors, enabling us to efficiently investigate and understand the key functionalities required for potency. Rational structure-based design coupled with a host of advanced computational methods, including FEP+ and WaterMap, were used to develop novel series of 15-PGDH inhibitors. Of note, a machine-learning (ML) model trained with potencies predicted by FEP+ yielded a powerful tool to guide synthetic priority across a large virtual chemical library. Ultimately, a lead compound demonstrated elevation of colonic PGE2 following IP administration in mice, consistent with our therapeutic hypothesis.
- Nimbus Therapeutics, Boston, Massachusetts 02210, United States.
Organizational Affiliation:
